Jasper Therapeutics Stock Performance
| JSPR Stock | USD 6.06 0.64 9.55% |
The company retains a Market Volatility (i.e., Beta) of 0.41, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Jasper Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Jasper Therapeutics is expected to be smaller as well. At this point, Jasper Therapeutics has a negative expected return of -1.45%. Please make sure to check out Jasper Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Jasper Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Jasper Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (9.55) | Five Day Return 7.83 | Year To Date Return (71.27) | Ten Year Return (93.83) | All Time Return (93.83) |
Last Split Factor 1:10 | Last Split Date 2024-01-04 |
1 | Disposition of 87531 shares by Martell Ron of Jasper Therapeutics at 1.46 subject to Rule 16b-3 | 11/08/2024 |
2 | Is Jasper Therapeutics the Best Multibagger Stock to Buy Heading into 2025 - Yahoo Finance | 11/15/2024 |
3 | Jasper Therapeutics Briquilimabs Potential In Chronic Urticaria And Asthma - Seeking Alpha | 11/18/2024 |
4 | Jasper Therapeutics Announces First Patient Dosed in Phase 1b2a ETESIAN Clinical Study of Briquilimab in Asthma | 12/02/2024 |
5 | Jasper Therapeutics shares rise on BMOs Outperform rating | 12/05/2024 |
6 | Acquisition by Mahal Jeetinder Singh of 900 shares of Jasper Therapeutics at 7.1 subject to Rule 16b-3 | 12/12/2024 |
7 | Fmr LLC Makes New 722,000 Investment in Jasper Therapeutics, Inc. - MarketBeat | 12/18/2024 |
8 | Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of ... | 01/06/2025 |
9 | Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic ... | 01/08/2025 |
10 | Jasper Therapeutics SWOT analysis briquilimabs potential in mast cell diseases | 01/10/2025 |
11 | Disposition of 900 shares by Mahal Jeetinder Singh of Jasper Therapeutics at 24.155 subject to Rule 16b-3 | 01/17/2025 |
12 | Top 19 most-performing biotech stocks of 2024 - Labiotech.eu | 01/27/2025 |
| Begin Period Cash Flow | 38.7 M |
Jasper |
Jasper Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,203 in Jasper Therapeutics on November 3, 2024 and sell it today you would lose (1,597) from holding Jasper Therapeutics or give up 72.49% of portfolio value over 90 days. Jasper Therapeutics is currently does not generate positive expected returns and assumes 9.2854% risk (volatility on return distribution) over the 90 days horizon. In different words, 82% of stocks are less volatile than Jasper, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Jasper Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Jasper Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Jasper Therapeutics, and traders can use it to determine the average amount a Jasper Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1559
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | JSPR |
Estimated Market Risk
| 9.29 actual daily | 82 82% of assets are less volatile |
Expected Return
| -1.45 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Jasper Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Jasper Therapeutics by adding Jasper Therapeutics to a well-diversified portfolio.
Jasper Therapeutics Fundamentals Growth
Jasper Stock prices reflect investors' perceptions of the future prospects and financial health of Jasper Therapeutics, and Jasper Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Jasper Stock performance.
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 475.2 K | ||||
| Shares Outstanding | 15 M | ||||
| Price To Book | 1.09 X | ||||
| EBITDA | (64.98 M) | ||||
| Net Income | (64.47 M) | ||||
| Cash And Equivalents | 60.81 M | ||||
| Cash Per Share | 1.60 X | ||||
| Total Debt | 2.79 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.56 X | ||||
| Book Value Per Share | 5.58 X | ||||
| Cash Flow From Operations | (52.07 M) | ||||
| Earnings Per Share | (4.75) X | ||||
| Market Capitalization | 90.91 M | ||||
| Total Asset | 94.89 M | ||||
| Retained Earnings | (169.6 M) | ||||
| Working Capital | 76.56 M | ||||
About Jasper Therapeutics Performance
Assessing Jasper Therapeutics' fundamental ratios provides investors with valuable insights into Jasper Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Jasper Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (406.40) | (386.08) | |
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (0.96) | (1.01) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (0.95) | (0.90) |
Things to note about Jasper Therapeutics performance evaluation
Checking the ongoing alerts about Jasper Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Jasper Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Jasper Therapeutics generated a negative expected return over the last 90 days | |
| Jasper Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (64.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Jasper Therapeutics currently holds about 60.81 M in cash with (52.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.6. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Top 19 most-performing biotech stocks of 2024 - Labiotech.eu |
- Analyzing Jasper Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Jasper Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Jasper Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Jasper Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Jasper Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Jasper Therapeutics' stock. These opinions can provide insight into Jasper Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.